ANL vs. SLRN, TRDA, OCS, FULC, LXRX, ANNX, TBPH, CRBP, LRMR, and TVTX
Should you be buying Adlai Nortye stock or one of its competitors? The main competitors of Adlai Nortye include Acelyrin (SLRN), Entrada Therapeutics (TRDA), Oculis (OCS), Fulcrum Therapeutics (FULC), Lexicon Pharmaceuticals (LXRX), Annexon (ANNX), Theravance Biopharma (TBPH), Corbus Pharmaceuticals (CRBP), Larimar Therapeutics (LRMR), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical preparations" industry.
Adlai Nortye (NASDAQ:ANL) and Acelyrin (NASDAQ:SLRN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings, valuation and community ranking.
Adlai Nortye currently has a consensus target price of $30.00, indicating a potential upside of 136.03%. Acelyrin has a consensus target price of $21.67, indicating a potential upside of 356.14%. Given Acelyrin's higher probable upside, analysts plainly believe Acelyrin is more favorable than Adlai Nortye.
Adlai Nortye has higher revenue and earnings than Acelyrin.
35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 87.3% of Acelyrin shares are owned by institutional investors. 13.6% of Acelyrin shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Adlai Nortye's return on equity of 0.00% beat Acelyrin's return on equity.
In the previous week, Acelyrin had 11 more articles in the media than Adlai Nortye. MarketBeat recorded 15 mentions for Acelyrin and 4 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 1.17 beat Acelyrin's score of 0.39 indicating that Adlai Nortye is being referred to more favorably in the media.
Acelyrin received 7 more outperform votes than Adlai Nortye when rated by MarketBeat users. However, 100.00% of users gave Adlai Nortye an outperform vote while only 61.11% of users gave Acelyrin an outperform vote.
Summary
Adlai Nortye and Acelyrin tied by winning 6 of the 12 factors compared between the two stocks.
Get Adlai Nortye News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adlai Nortye Competitors List
Related Companies and Tools
